High rate of sustained virologic response with the all- oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV genotype 1, 2, or 3

Authors
Category Primary study
ConferenceHepatology
Year 2012
This article has no abstract
Epistemonikos ID: 605b8017c623880e47be2c8c45ad6c0771f1fa8f
First added on: Apr 30, 2026